Carna Biosciences, Inc. reported consolidated financial results for the nine months ended Sep. 30, 2017. For the nine months, the company reported operating loss of ¥477 million and loss attributable to owners of parent of ¥508 million or ¥54.46 per basic share on net sales of ¥483 million against operating loss of ¥334 million and loss attributable to owners of parent of ¥178 million or ¥19.52 per basic share on net sales of ¥581 million for the same period of last year. Loss before income taxes was ¥505.4 million against ¥176.6 million for the same period of last year.

For the year ending Dec. 31, 2017, the company expects, operating loss of ¥727 million and loss attributable to owners of parent of ¥766 million or ¥82.12 per basic share on net sales of ¥701 million.